{
  "meta": {
    "title": "Complications_Of_Diabetes_Mellitus",
    "url": "https://brainandscalpel.vercel.app/complications-of-diabetes-mellitus-248aba88.html",
    "scrapedAt": "2025-11-29T18:24:43.534Z"
  },
  "questions": [
    {
      "id": 19945,
      "choices": [
        {
          "id": 79741,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In 3 months </span></span></span></p>"
        },
        {
          "id": 79742,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In 6 months </span></span></span></p>"
        },
        {
          "id": 79743,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In 1 year </span></span></span></p>"
        },
        {
          "id": 79744,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In 5 years</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 50-year-old patient with newly diagnosed type 2 diabetes mellitus (T2DM) has a negative urine microalbumin test. When should the next urine microalbumin test be repeated?</span></span></p>",
      "unique_key": "Q6840122",
      "question_audio": null,
      "question_video": null,
      "map_id": 19919,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) In 1 year</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Annual screening for microalbuminuria is recommended for patients with type 2 diabetes to detect early signs of diabetic nephropathy (kidney disease). A negative test result indicates no current evidence of kidney damage, therefore, the next screening should be done in a year.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/20/screenshot-2024-08-20-094813.png\" style=\"height:477px; width:1000px\" /></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. In 3 months:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Too frequent for routine screening and not necessary with a negative initial test.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. In 6 months:</span></strong><span style=\"font-size:12.0pt\">&nbsp;While more frequent screening may be indicated in some cases,&nbsp;annual testing is generally sufficient for initial monitoring.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. In 5 years:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Too infrequent for monitoring diabetic nephropathy,&nbsp;as significant damage could occur undetected in this time frame.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Annual screening for microalbuminuria is recommended in type 2 diabetes to detect early signs of diabetic nephropathy.</span></span></span></p>",
      "correct_choice_id": 79743,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19937,
      "choices": [
        {
          "id": 79709,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Diabetic dermopathy </span></span></span></p>"
        },
        {
          "id": 79710,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Necrobiosis lipoidica diabeticorum </span></span></span></p>"
        },
        {
          "id": 79711,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lichen planus </span></span></span></p>"
        },
        {
          "id": 79712,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Scleredema</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 54-year-old man with long-standing diabetes presents with the lesion shown in the image. Identify the condition:</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/20/screenshot-2024-08-20-093055.png\" style=\"height:217px; width:300px\" /></span></span></p>",
      "unique_key": "Q9121333",
      "question_audio": null,
      "question_video": null,
      "map_id": 19911,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Diabetic dermopathy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The image shows multiple, well-defined, hyperpigmented atrophic macules over both shins, which is characteristic of diabetic dermopathy. Diabetic dermopathy, also known as shin spots, is the most common cutaneous manifestation of diabetes mellitus. It is caused by changes in the small blood vessels of the skin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Necrobiosis lipoidica diabeticorum:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This condition presents as larger,&nbsp;yellowish-brown patches with a raised,&nbsp;reddish border,&nbsp;often located on the shins.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Lichen planus:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This inflammatory skin condition presents as purple,&nbsp;itchy,&nbsp;flat-topped bumps.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Scleredema:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This condition is characterized by thickening and hardening of the skin,&nbsp;usually on the back or neck.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diabetic dermopathy, characterized by hyperpigmented atrophic macules over the shins, is the most common cutaneous manifestation of diabetes.</span></span></span></p>",
      "correct_choice_id": 79709,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54043,
      "choices": [
        {
          "id": 215641,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulinoma </span></span></span></p>"
        },
        {
          "id": 215642,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Factitious hypoglycemia due to sulfonylurea</span></span></span></p>"
        },
        {
          "id": 215643,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Non-insulin-mediated hypoglycemia </span></span></span></p>"
        },
        {
          "id": 215644,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IGF-2 related hypoglycemia</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old man presents with recurrent hypoglycemia, confirmed by Whipple&#39;s triad. Laboratory investigations reveal a beta-hydroxybutyrate (&beta;-OHB) level of 5 mmol/L and a poor blood glucose response to glucagon. The most likely diagnosis is:</span></span></p>",
      "unique_key": "Q3868642",
      "question_audio": null,
      "question_video": null,
      "map_id": 25636,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Non-insulin-mediated hypoglycemia</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Elevated &beta;-OHB levels&nbsp;</span></strong><span style=\"font-size:12.0pt\">and&nbsp;<strong>Poor response to glucagon </strong>indicated that the hypoglycemia is not mediated by insulin or insulin like factors (IGF-2). Examples include critical illness, organ failure (liver, kidney), sepsis, counter-regulatory hormone deficiencies (GH/cortisol) etc. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Insulinoma:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This would typically present with suppressed ketone levels due to the inhibitory effect of excess insulin on lipolysis and ketogenesis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Factitious hypoglycemia due to sulfonylurea:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Sulfonylureas increase insulin secretion,&nbsp;and hypoglycemia due to these medications would and tend to have suppressed &beta;-OHB (&lt; 2.7 mmol/L) in view of hyperinsulinemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. IGF-2 related hypoglycemia:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This is a rare cause of hypoglycemia and tend to have suppressed &beta;-OHB (&lt; 2.7 mmol/L) in view of insulin like action. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Elevated &beta;-OHB levels and poor response to glucagon indicate non-insulin-mediated hypoglycemia, such as critical illness or organ failure.</span></span></span></p>",
      "correct_choice_id": 215643,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19947,
      "choices": [
        {
          "id": 79749,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Discontinue the insulin infusion </span></span></span></p>"
        },
        {
          "id": 79750,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Switch to subcutaneous insulin </span></span></span></p>"
        },
        {
          "id": 79751,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add dextrose to the intravenous fluids </span></span></span></p>"
        },
        {
          "id": 79752,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increase the rate of the insulin infusion</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old man with type 2 diabetes presents to the emergency department with DKA. His initial blood glucose level is 650 mg/dL. After 6 hours of treatment with intravenous fluids and insulin, his blood glucose drops to 200 mg/dL. Which of the following is the most appropriate next step in management?</span></span></p>",
      "unique_key": "Q8201858",
      "question_audio": null,
      "question_video": null,
      "map_id": 19921,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Add dextrose to the intravenous fluids</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">When the blood glucose level drops to 200-250 mg/dL during DKA treatment, it is crucial to add dextrose to the intravenous fluids to prevent hypoglycemia and to maintain a target plasma glucose is 150-200 mg/dL. Insulin infusion can thus, be continued at a lower rate to ensure correction of ketoacidosis. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Discontinue the insulin infusion:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Insulin should not be discontinued until the ketoacidosis is resolved,&nbsp;as indicated by a normal anion gap and beta-hydroxybutyrate level.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Switch to subcutaneous insulin:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Subcutaneous insulin is not appropriate in the acute management of DKA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Increase the rate of the insulin infusion:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Increasing the insulin infusion rate could lead to hypoglycemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">When blood glucose drops to 200-250 mg/dL during DKA treatment, add dextrose to IV fluids to prevent hypoglycemia and continue insulin infusion.</span></span></span></p>",
      "correct_choice_id": 79751,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19932,
      "choices": [
        {
          "id": 79689,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">3% NaCl </span></span></span></p>"
        },
        {
          "id": 79690,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IV fluids </span></span></span></p>"
        },
        {
          "id": 79691,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin infusion </span></span></span></p>"
        },
        {
          "id": 79692,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Potassium supplementation</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A young woman with type 1 diabetes presents to the emergency department with diabetic ketoacidosis (DKA) after stopping insulin. On examination, she is delirious and initial laboratory reports show:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">S. Na 128 mEq/L, S. K+ 4.3 mEq/L, BUN 76 mg/dL, S. Cr 2.2 mg/dL, S. HCO3- 10 mEq/L, Blood glucose 520 mg/dL. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following is NOT an appropriate treatment?</span></span></span></p>",
      "unique_key": "Q4323650",
      "question_audio": null,
      "question_video": null,
      "map_id": 19906,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) 3% NaCl</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient presents with pseudohyponatremia, which is a falsely low sodium level due to the presence of hyperglycemia. The corrected sodium level can be calculated using the following formula:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Corrected Sodium = Measured Sodium + 1.6 mEq/L * (Serum Glucose [mg/dL] - 100 mg/dL) / 100</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In this case, the corrected sodium is:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Corrected Sodium = 128 mEq/L + 1.6 mEq/L * (520 mg/dL - 100 mg/dL) / 100 = 135 mEq/L</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Since the corrected sodium is within the normal range (135-145 mEq/L), administering hypertonic saline (3% NaCl) is not indicated. In fact, it could be harmful by worsening hyperosmolar state. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. 0.9% sodium chloride (NaCl):</span></strong><span style=\"font-size:12.0pt\"> This isotonic fluid is appropriate for rehydration in DKA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Insulin infusion:</span></strong><span style=\"font-size:12.0pt\"> This is essential to lower blood glucose levels and correct ketoacidosis in DKA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Potassium supplementation:</span></strong><span style=\"font-size:12.0pt\"> While initial potassium levels are normal, they can drop rapidly with insulin therapy. Therefore, potassium supplementation is often necessary during DKA treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypertonic saline (3% NaCl) is not indicated in DKA with pseudohyponatremia; it could worsen the hyperosmolar state.</span></span></span></p>",
      "correct_choice_id": 79689,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19949,
      "choices": [
        {
          "id": 79757,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IV Aspart </span></span></span></p>"
        },
        {
          "id": 79758,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IV KCl </span></span></span></p>"
        },
        {
          "id": 79759,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IV NaHCO3 </span></span></span></p>"
        },
        {
          "id": 79760,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CT head</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 17-year-old boy with type 1 diabetes presents with vomiting, abdominal pain, lethargy, and drowsiness. His blood glucose is 350 mg/dL, and ABG shows the following &ndash; pH 7.24, S. Na 130 mEq/L, S. K 3.0 mEq/L, S. HCO3- 14 mEq/L, and S. Cl 88 mEq/L. His BP is 90/60 mm Hg, and IV fluids were rushed. Which of the following is the most appropriate next step in management?</span></span></p>",
      "unique_key": "Q6280882",
      "question_audio": null,
      "question_video": null,
      "map_id": 19923,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) IV KCl</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient is presenting with diabetic ketoacidosis (DKA) based on the clinical presentation (vomiting, abdominal pain, lethargy, drowsiness), elevated blood glucose (350 mg/dL), and metabolic acidosis on ABG (pH 7.24, bicarbonate 14 mEq/L). The patient also has significant hypokalemia (K+ 3.0 mEq/L) which is a common electrolyte disturbance in DKA due to increased urinary potassium loss.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Hypokalemia and Insulin:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Insulin administration can further exacerbate hypokalemia by shifting potassium from the extracellular to the intracellular space.&nbsp;Therefore,&nbsp;potassium replacement should be initiated before starting insulin therapy in DKA.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. IV Aspart:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Insulin therapy is essential in DKA but should be started after correcting hypokalemia. Regular insulin is preferred for IV use in view of lesser cost but rapid acting analogs can also be used for IV use and are not contraindicated. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. IV NaHCO3:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Sodium bicarbonate is generally not recommended in DKA unless the pH is less than 6.9 or there are significant cardiac complications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. CT head:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Cerebral edema is a rare complication of DKA and usually occurs in children during treatment. It is not the immediate priority in this scenario.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Administer IV potassium chloride to correct hypokalemia before initiating insulin therapy in DKA to prevent severe hypokalemia.</span></span></span></p>",
      "correct_choice_id": 79758,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19931,
      "choices": [
        {
          "id": 79685,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Arterial pH &gt;7.3 </span></span></span></p>"
        },
        {
          "id": 79686,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Elevated plasma ketones </span></span></span></p>"
        },
        {
          "id": 79687,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Osmolality &lt;320 mOsm/mL </span></span></span></p>"
        },
        {
          "id": 79688,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sodium &lt;135 mEq/L</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following laboratory values is typically seen in hyperglycemic hyperosmolar state (HHS) and not in diabetic ketoacidosis (DKA)?</span></span></p>",
      "unique_key": "Q9495273",
      "question_audio": null,
      "question_video": null,
      "map_id": 19905,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Arterial pH &gt;7.3</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In hyperglycemic hyperosmolar state (HHS), the arterial pH is typically normal or near normal (&gt;7.3) due to the absence of significant ketoacidosis. This is in contrast to diabetic ketoacidosis (DKA), where the accumulation of ketone bodies leads to metabolic acidosis and a lower arterial pH (&lt;7.3).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Elevated plasma ketones:</span></strong><span style=\"font-size:12.0pt\"> This is a hallmark of DKA, not HHS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Osmolality &lt;320 mOsm/mL:</span></strong><span style=\"font-size:12.0pt\"> Hyperosmolarity can occur in both DKA and HHS but DKA patients tend to have a serum osmolality of &lt; 320 mOsm/L. HHS patients typically have a serum osmolality of &gt; 320 mOsm/L (due to extreme hyperglycemia). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Sodium &lt;135 mEq/L:</span></strong><span style=\"font-size:12.0pt\"> Hyponatremia (low sodium) can occur in both DKA and HHS but it is less pronounced and it is often normal in HHS (in view of severe dehydration and water loss). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In HHS, the arterial pH is typically normal or near normal (&gt;7.3) due to the absence of significant ketoacidosis.</span></span></span></p>",
      "correct_choice_id": 79685,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19933,
      "choices": [
        {
          "id": 79693,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cheiroarthropathy </span></span></span></p>"
        },
        {
          "id": 79694,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Macular edema </span></span></span></p>"
        },
        {
          "id": 79695,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Infections </span></span></span></p>"
        },
        {
          "id": 79696,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Feet Claudication</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following complications of diabetes mellitus is due to microvascular disease?</span></span></p>",
      "unique_key": "Q4327298",
      "question_audio": null,
      "question_video": null,
      "map_id": 19907,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Macular edema</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diabetic Macular edema is microvascular complication of diabetes mellitus. Macular edema is a complication of diabetic retinopathy, which is a microvascular disease affecting the small blood vessels in the retina. It occurs due to increased vascular permeability and leakage of fluid into the macula, leading to blurred vision. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Cheiroarthropathy:</span></strong><span style=\"font-size:12.0pt\"> This refers to hand stiffness and joint changes, which are not primarily caused by microvascular disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Infections:</span></strong><span style=\"font-size:12.0pt\"> While diabetes can increase susceptibility to infections, it is not a direct consequence of microvascular disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Feet Claudication:</span></strong><span style=\"font-size:12.0pt\"> Claudication (pain with exertion) is a symptom of peripheral artery disease, which is a macrovascular complication of diabetes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Summary:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Microvascular complications (diabetes specific):</span></strong><span style=\"font-size:12.0pt\"> Retinopathy, macular edema, neuropathy, nephropathy (diabetic kidney disease). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Macrovascular complications:</span></strong><span style=\"font-size:12.0pt\"> CAD, PAD and cerebrovascular disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Nonvascular/multifactorial complications:</span></strong><span style=\"font-size:12.0pt\"> Infections, skin changes, cheiroarthropathy, cataract, glaucoma, periodontal disease, GI/GU complications and hearing loss. Some studies suggest that type 2 DM increases the risk of dementia and impaired cognitive function.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diabetic macular edema is a microvascular complication of diabetes, caused by increased vascular permeability and fluid leakage into the macula</span></span></span></p>",
      "correct_choice_id": 79694,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19934,
      "choices": [
        {
          "id": 79697,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diabetic amyotrophy </span></span></span></p>"
        },
        {
          "id": 79698,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Distal symmetric polyneuropathy </span></span></span></p>"
        },
        {
          "id": 79699,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Herniation of a lumbar disk </span></span></span></p>"
        },
        {
          "id": 79700,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Meralgia paresthetica</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 74-year-old man with poorly controlled type 2 diabetes presents with sudden-onset, severe right thigh pain and weakness. His sensory examination is normal. MRI of the lower spine is unremarkable. What is the most likely cause of his symptoms?</span></span></p>",
      "unique_key": "Q2228263",
      "question_audio": null,
      "question_video": null,
      "map_id": 19908,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Diabetic amyotrophy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diabetic amyotrophy (also known as diabetic lumbosacral radiculoplexus neuropathy) is a microvascular complication of diabetes that affects the nerves supplying the proximal leg muscles, causing pain, weakness, and muscle wasting. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Distal symmetric polyneuropathy:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This typically affects the feet and hands first,&nbsp;causing sensory symptoms before motor weakness.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Herniation of a lumbar disk:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This would usually present with radicular pain and sensory changes,&nbsp;which are absent in this case. Also, MRI would have revealed the herniation. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Meralgia paresthetica:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This causes numbness and tingling in the outer thigh due to compression of the lateral femoral cutaneous nerve,&nbsp;but not severe pain or weakness.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diabetic amyotrophy is a microvascular complication affecting the nerves supplying proximal leg muscles, causing pain and weakness.</span></span></span></p>",
      "correct_choice_id": 79697,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19935,
      "choices": [
        {
          "id": 79701,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Suppression of Insulin release</span></span></span></p>"
        },
        {
          "id": 79702,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Release of Cortisol </span></span></span></p>"
        },
        {
          "id": 79703,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Release of Glucagon </span></span></span></p>"
        },
        {
          "id": 79704,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Release of Epinephrine</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following hormones has a delayed response in the defense against acute hypoglycemia?</span></span></p>",
      "unique_key": "Q6877377",
      "question_audio": null,
      "question_video": null,
      "map_id": 19909,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Release of Cortisol</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cortisol and growth hormone although involved in glucose counter-regulation, has a delayed response. It primarily supports glucose production during prolonged hypoglycemia (lasting more than 4 hours) and thus, cortisol and growth hormone play no role in defense against acute hypoglycemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Suppression of Insulin release:</span></strong><span style=\"font-size:12.0pt\">&nbsp;First line of defense in hypoglycemia. Insulin release is reduced at plasma glucose levels of &lt; 80-85 mg/dL and almost shuts off if levels are &lt; 70 mg/dL. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Release of Glucagon:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Second line of defense in acute hypoglycemia. Kicks off once glucose levels are &lt; 65-70 mg/dL. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Release of Epinephrine:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Import ant especially in glucagon deficient states. Kicks off once glucose levels are &lt; 65-70 mg/dL.&nbsp;</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cortisol has a delayed response in hypoglycemia, primarily supporting glucose production during prolonged hypoglycemia.</span></span></span></p>",
      "correct_choice_id": 79702,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19936,
      "choices": [
        {
          "id": 79705,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Diabetic dermopathy </span></span></span></p>"
        },
        {
          "id": 79706,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Xerosis </span></span></span></p>"
        },
        {
          "id": 79707,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Necrobiosis lipoidica diabeticorum </span></span></span></p>"
        },
        {
          "id": 79708,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acanthosis nigricans</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">What is the most common cutaneous manifestation of diabetes mellitus?</span></span></span></p>",
      "unique_key": "Q5947994",
      "question_audio": null,
      "question_video": null,
      "map_id": 19910,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Xerosis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Xerosis and pruritis are the most common cutaneous manifestations of diabetes mellitus. They are usually relieved by skin moisturizers. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Diabetic dermopathy:</span></strong><span style=\"font-size:12.0pt\">&nbsp; Sometimes termed pigmented pretibial papules, or &ldquo;diabetic skin spots,&rdquo; begins as an erythematous macule or papule that evolves into an area of circular hyperpigmentation. These lesions result from minor mechanical trauma in the pretibial region and are more common in elderly men with DM.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Necrobiosis lipoidica diabeticorum:</span></strong><span style=\"font-size:12.0pt\">&nbsp;It is an uncommon disorder, accompanying diabetes in predominantly young women. This usually begins in the pretibial region as an erythematous plaque or papules that gradually enlarge, darken, and develop irregular margins, with atrophic centers and central ulceration. They are often painful. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Acanthosis nigricans:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This is a velvety,&nbsp;hyperpigmented skin condition associated with insulin resistance.&nbsp;It is not the most common skin finding in diabetes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Xerosis (dry skin) and pruritis are the most common cutaneous manifestations of diabetes mellitus.</span></span></span></p>",
      "correct_choice_id": 79706,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19938,
      "choices": [
        {
          "id": 79713,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Microaneurysms </span></span></span></p>"
        },
        {
          "id": 79714,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Neovascularization </span></span></span></p>"
        },
        {
          "id": 79715,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Papilledema </span></span></span></p>"
        },
        {
          "id": 79716,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Retinal detachment</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 55-year-old man with long-standing type 2 diabetes mellitus undergoes an ophthalmologic examination. What is the most likely finding seen on his funduscopic examination?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/20/screenshot-2024-08-20-093301.png\" style=\"height:210px; width:300px\" /></span></span></span></p>",
      "unique_key": "Q6044001",
      "question_audio": null,
      "question_video": null,
      "map_id": 19912,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Neovascularization</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The funduscopic image shows characteristic signs of proliferative diabetic retinopathy, the most significant of which is neovascularization. This is the growth of new blood vessels on the retina, which are fragile and prone to bleeding, leading to vision loss.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Microaneurysms:</span></strong><span style=\"font-size:12.0pt\">&nbsp;While microaneurysms are an early sign of diabetic retinopathy,&nbsp;they are not the defining characteristic of proliferative retinopathy seen in this image.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Papilledema:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This is swelling of the optic disc due to increased intracranial pressure and is not associated with diabetic retinopathy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Retinal detachment:</span></strong><span style=\"font-size:12.0pt\">&nbsp;While a potential complication of proliferative diabetic retinopathy,&nbsp;it is not directly visible in this image.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Neovascularization is the hallmark of proliferative diabetic retinopathy, characterized by the growth of new blood vessels on the retina.</span></span></span></p>",
      "correct_choice_id": 79714,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19939,
      "choices": [
        {
          "id": 79717,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increase dose of statins </span></span></span></p>"
        },
        {
          "id": 79718,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add fenofibrate </span></span></span></p>"
        },
        {
          "id": 79719,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add Icosapent ethyl </span></span></span></p>"
        },
        {
          "id": 79720,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Change statins to PCSK9 inhibitor</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 44-year-old diabetic patient with CAD presents to you with routine blood tests. His LDL levels were within target (68 mg/dL) but his triglyceride levels were elevated (350 mg/dL). What can be done next to reduce his CV risk?</span></span></p>",
      "unique_key": "Q7771768",
      "question_audio": null,
      "question_video": null,
      "map_id": 19913,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Add Icosapent ethyl</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient has hypertriglyceridemia (triglycerides &gt;150 mg/dL) despite being on statin therapy and having LDL cholesterol under control. Icosapent ethyl is a highly purified form of eicosapentaenoic acid (EPA), an omega-3 fatty acid, that has been shown to significantly reduce cardiovascular risk in patients with elevated triglyceride levels, even when already on statin therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Increase dose of statins:</span></strong><span style=\"font-size:12.0pt\">&nbsp;While statins can modestly lower triglycerides, their primary effect is on LDL cholesterol. Increasing the statin dose may not significantly reduce triglycerides and could increase the risk of side effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Add fenofibrate:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Fibrates can effectively lower triglycerides, but they have not been shown to reduce cardiovascular events in patients already on statin therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Change statins to PCSK9 inhibitor:</span></strong><span style=\"font-size:12.0pt\">&nbsp;PCSK9 inhibitors are potent LDL-lowering drugs but have limited effects on triglycerides. They would not be the most appropriate choice in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Icosapent ethyl, an omega-3 fatty acid, significantly reduces cardiovascular risk in patients with elevated triglycerides despite being on statin therapy.</span></span></span></p>",
      "correct_choice_id": 79719,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19940,
      "choices": [
        {
          "id": 79721,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rapid control of blood sugars </span></span></span></p>"
        },
        {
          "id": 79722,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fenofibrate </span></span></span></p>"
        },
        {
          "id": 79723,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pregnancy </span></span></span></p>"
        },
        {
          "id": 79724,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diabetic nephropathy</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All of the following result in worsening of diabetic retinopathy except?</span></span></span></p>",
      "unique_key": "Q9762707",
      "question_audio": null,
      "question_video": null,
      "map_id": 19914,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Fenofibrate</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fenofibrate, a fibrate medication used to treat dyslipidemia, has been shown to have a potential beneficial effect on diabetic retinopathy. It may help reduce the progression of the disease by lowering triglyceride levels and improving blood lipid profiles.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Rapid control of blood sugars:</span></strong><span style=\"font-size:12.0pt\">&nbsp;While tight glycemic control is essential for the long-term management of diabetic retinopathy,&nbsp;rapid improvement in blood sugar levels can sometimes lead to a temporary worsening of retinopathy in the short term (6-12 months). Individuals with known retinopathy may be candidates for prophylactic laser photocoagulation when initiating intensive therapy, and especially prior to pancreas or islet transplantation that can rapidly normalize glycemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Pregnancy:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Hormonal changes and increased metabolic demands during pregnancy can exacerbate diabetic retinopathy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Diabetic nephropathy:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Kidney disease in diabetes is often associated with worsened retinopathy due to shared microvascular damage and potential alterations in growth factors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fenofibrate may help reduce the progression of diabetic retinopathy by lowering triglyceride levels and improving blood lipid profiles.</span></span></span></p>",
      "correct_choice_id": 79722,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19941,
      "choices": [
        {
          "id": 79725,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increased heart rate variability </span></span></span></p>"
        },
        {
          "id": 79726,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Orthostatic hypotension </span></span></span></p>"
        },
        {
          "id": 79727,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Resting tachycardia </span></span></span></p>"
        },
        {
          "id": 79728,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prolonged QT interval</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following does NOT occur in diabetic autonomic neuropathy (DAN)?</span></span></span></p>",
      "unique_key": "Q4075358",
      "question_audio": null,
      "question_video": null,
      "map_id": 19915,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Increased heart rate variability</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">DAN typically causes&nbsp;<strong>decreased</strong>&nbsp;heart rate variability due to impaired autonomic regulation of the heart.&nbsp;This is a significant finding that can be detected on electrocardiogram (ECG) or Holter monitoring.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Orthostatic hypotension:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This is a common feature of DAN due to impaired sympathetic nervous system response,&nbsp;leading to a drop in blood pressure upon standing.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Resting tachycardia:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This is also frequently seen in DAN due to parasympathetic dysfunction,&nbsp;leading to a faster resting heart rate.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Prolonged QT interval:</span></strong><span style=\"font-size:12.0pt\">&nbsp;DAN can affect cardiac conduction,&nbsp;leading to a prolonged QT interval and increased risk of arrhythmias.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Decreased heart rate variability is seen in DAN due to impaired autonomic regulation of the heart.</span></span></span></p>",
      "correct_choice_id": 79725,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19942,
      "choices": [
        {
          "id": 79729,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Most common form is DSPN (Distal Symmetric Polyneuropathy) </span></span></span></p>"
        },
        {
          "id": 79730,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glycemic control can worsen neuropathic pain initially </span></span></span></p>"
        },
        {
          "id": 79731,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients can be asymptomatic </span></span></span></p>"
        },
        {
          "id": 79732,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Loss of knee jerk is common</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is incorrect regarding diabetic neuropathy?</span></span></p>",
      "unique_key": "Q1441568",
      "question_audio": null,
      "question_video": null,
      "map_id": 19916,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Loss of knee jerk is common</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diabetic neuropathy often affects the longest nerves first, which are the peripheral nerves in the feet and legs. The loss of ankle jerk reflexes is a common finding, while the knee jerk reflex is typically preserved.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Most common form is DSPN:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This is true.&nbsp;DSPN is the most prevalent form of diabetic neuropathy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Glycemic control can worsen neuropathic pain initially:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This is true.&nbsp;In some cases,&nbsp;rapid improvement in glycemic control can paradoxically worsen neuropathic pain in the short term.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Patients can be asymptomatic:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Many patients (up to 50%) with diabetic neuropathy,&nbsp;especially in the early stages,&nbsp;do not experience any symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diabetic neuropathy typically affects the peripheral nerves in the feet and legs first, with loss of ankle jerk reflexes being common.</span></span></span></p>",
      "correct_choice_id": 79732,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19943,
      "choices": [
        {
          "id": 79733,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Blood sugar of 340 mg/dL </span></span></span></p>"
        },
        {
          "id": 79734,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Serum bicarbonate of 22 mEq/L </span></span></span></p>"
        },
        {
          "id": 79735,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anion gap of 8 mEq/L </span></span></span></p>"
        },
        {
          "id": 79736,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Beta-hydroxybutyrate (&beta;-OHB) level of 5 mmol/L</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with type 1 diabetes presents with vomiting, abdominal pain and tachycardia. Which laboratory finding would be consistent with the diagnosis of euglycemic ketoacidosis (EDKA)?</span></span></p>",
      "unique_key": "Q5443871",
      "question_audio": null,
      "question_video": null,
      "map_id": 19917,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Beta-hydroxybutyrate (&beta;-OHB) level of 5 mmol/L</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Euglycemic ketoacidosis (EDKA) is a form of diabetic ketoacidosis (DKA) where ketone levels are elevated, leading to metabolic acidosis, but blood glucose levels are near normal or only slightly elevated.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">&beta;-OHB level of 5 mmol/L:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Elevated beta-hydroxybutyrate is a key ketone body and a hallmark of ketoacidosis.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">The symptoms</span></strong><span style=\"font-size:12.0pt\">&nbsp;of vomiting and abdominal pain are common in DKA and EDKA.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Blood sugar of 340 mg/dL:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This is a high blood sugar level,&nbsp;typical of DKA,&nbsp;not EDKA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Serum bicarbonate of 22 mEq/L:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This is a normal HCO3- level and wouldn&#39;t indicate acidosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Anion gap of 8 mEq/L:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This is a normal anion gap and wouldn&#39;t indicate acidosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Elevated &beta;-OHB levels indicate ketoacidosis, even when blood glucose levels are near normal, characteristic of euglycemic ketoacidosis.</span></span></span></p>",
      "correct_choice_id": 79736,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19944,
      "choices": [
        {
          "id": 79737,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Malignant otitis externa </span></span></span></p>"
        },
        {
          "id": 79738,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">UTI </span></span></span></p>"
        },
        {
          "id": 79739,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Pneumonia </span></span></span></p>"
        },
        {
          "id": 79740,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Tuberculosis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following infection is a hallmark of diabetes mellitus?</span></span></p>",
      "unique_key": "Q1828756",
      "question_audio": null,
      "question_video": null,
      "map_id": 19918,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Malignant otitis externa</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Malignant (invasive) otitis externa is a severe, potentially life-threatening infection of the external ear canal. It is particularly associated with diabetes mellitus, especially in older adults. Invasive otitis externa is usually secondary to Pseudomonas aeruginosa infection. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Many common infections are more frequent and severe in the diabetic population, whereas several rare infections are seen almost exclusively in the diabetic population. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Examples of this latter category include rhinocerebral mucormycosis, emphysematous infections of the gallbladder and urinary tract, and &ldquo;malignant&rdquo; or invasive otitis externa. </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. UTI:</span></strong><span style=\"font-size:12.0pt\">&nbsp;While urinary tract infections (UTIs) are more common in people with diabetes,&nbsp;they are not considered a hallmark infection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Pneumonia:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Pneumonia can occur in people with diabetes,&nbsp;but it&#39;s not specific to this condition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Tuberculosis:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Diabetes can increase the risk of tuberculosis (TB),&nbsp;but it&#39;s not a hallmark infection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Malignant otitis externa, a severe ear infection often caused by Pseudomonas aeruginosa, is particularly associated with diabetes mellitus.</span></span></span></p>",
      "correct_choice_id": 79737,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19946,
      "choices": [
        {
          "id": 79745,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Abscess/cellulitis</span></span></span></p>"
        },
        {
          "id": 79746,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Charcot neuroarthropathy </span></span></span></p>"
        },
        {
          "id": 79747,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diabetic foot osteomyelitis </span></span></span></p>"
        },
        {
          "id": 79748,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Traumatic fracture</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 56-year-old woman with diabetes, hypertension, retinopathy, and peripheral neuropathy presents with 6 weeks of dull aching foot pain. Examination reveals bounding pulses and elevated temperature in the left foot, but no ulcers. What is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q9658973",
      "question_audio": null,
      "question_video": null,
      "map_id": 19920,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Charcot neuroarthropathy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Charcot neuroarthropathy is a degenerative joint disease often associated with diabetes and neuropathy. It presents with chronic, dull pain, bounding pulses, and increased temperature in the affected foot, even without ulcers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Abscess/cellulitis:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Typically presents with acute pain,&nbsp;redness,&nbsp;and swelling.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Diabetic foot osteomyelitis:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Usually associated with fever and elevated inflammatory markers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Traumatic fracture:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Requires a history of trauma and would present with more acute pain.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Charcot neuroarthropathy presents with chronic dull pain, bounding pulses, and increased temperature in the foot, often associated with diabetes and neuropathy.</span></span></span></p>",
      "correct_choice_id": 79746,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19948,
      "choices": [
        {
          "id": 79753,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Administer intravenous regular insulin at 0.1 units/kg/hour</span></span></span></p>"
        },
        {
          "id": 79754,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Correct hypokalemia with intravenous potassium chloride before initiating insulin therapy</span></span></span></p>"
        },
        {
          "id": 79755,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Administer intravenous sodium bicarbonate to correct acidosis</span></span></span></p>"
        },
        {
          "id": 79756,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Obtain a head CT scan to rule out cerebral edema</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 17-year-old boy with type 1 diabetes presents with vomiting, abdominal pain, lethargy and drowsiness. His blood glucose is 350 mg/dL, and ABG shows the following &ndash; pH 7.24, S. Na 130 mEq/L, S. K 3.0 mEq/L, S. HCO3- 14 mEq/L and S. Cl 88 mEq/L. His BP is 90/60 mm Hg and IV fluids were started. Which of the following is the most appropriate next step in management?</span></span></span></p>",
      "unique_key": "Q5464208",
      "question_audio": null,
      "question_video": null,
      "map_id": 19922,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Correct hypokalemia with intravenous potassium chloride before initiating insulin therapy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient presents with DKA and hypokalemia. Hypokalemia is a common complication of DKA and can be life-threatening if not corrected before initiating insulin therapy. Insulin drives potassium into cells, potentially worsening hypokalemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Administer intravenous regular insulin at 0.1 units/kg/hour:</span></strong><span style=\"font-size:12.0pt\">&nbsp;While insulin is necessary for DKA management,&nbsp;it should not be initiated before correcting hypokalemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Administer intravenous sodium bicarbonate to correct acidosis:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Sodium bicarbonate is generally not recommended in DKA unless the pH is less than 6.9 or there is significant cardiac instability.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Obtain a head CT scan to rule out cerebral edema:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Cerebral edema is a rare but serious complication of DKA,&nbsp;but it is not the most appropriate next step in management in this patient with hypokalemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Correct hypokalemia before initiating insulin therapy in DKA to prevent further potassium depletion and cardiac complications.</span></span></span></p>",
      "correct_choice_id": 79754,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19950,
      "choices": [
        {
          "id": 79761,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Alcohol-induced hypoglycemia </span></span></span></p>"
        },
        {
          "id": 79762,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypoglycemia in type 1 diabetes </span></span></span></p>"
        },
        {
          "id": 79763,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sulfonylurea-related hypoglycemia </span></span></span></p>"
        },
        {
          "id": 79764,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypoglycemia due to insulinoma</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which among the following situations is glucagon most effective?</span></span></p>",
      "unique_key": "Q1889006",
      "question_audio": null,
      "question_video": null,
      "map_id": 19924,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Hypoglycemia in type 1 diabetes</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucagon works by stimulating glycogenolysis &gt; gluconeogenesis, causing blood sugar levels to rise. Glucagon also stimulates insulin release from &beta; cells; however, since patients with type 1 diabetes lack insulin production, glucagon can effectively raise blood glucose levels without an increase in insulin. Hence, it is an effective treatment for hypoglycemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Alcohol-induced hypoglycemia:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Alcohol impairs gluconeogenesis and most patients will be glycogen depleted (due to malnutrition) limiting the effectiveness of glucagon.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Sulfonylurea-related hypoglycemia:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Glucagon stimulate insulin release which can have a synergistic effect with sulfonylureas and can cause rebound severe hypoglycemia. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Hypoglycemia due to insulinoma:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Glucagon stimulate excessive insulin release from insulinoma which can result in dangerous hypoglycemia and hence contraindicated. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucagon effectively raises blood glucose levels in hypoglycemia by stimulating glycogenolysis, especially in type 1 diabetes where there is no insulin production.</span></span></span></p>",
      "correct_choice_id": 79762,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54044,
      "choices": [
        {
          "id": 215645,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CECT Abdomen </span></span></span></p>"
        },
        {
          "id": 215646,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Selective arterial calcium stimulation </span></span></span></p>"
        },
        {
          "id": 215647,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Measure serum IGF 2 levels</span></span></span></p>"
        },
        {
          "id": 215648,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Test for insulin autoantibodies</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old man presents with weight gain and recurrent hypoglycemia. Laboratory investigations reveal a low beta-hydroxybutyrate (&beta;-OHB) level (0.2 mmol/L). His C-peptide and plasma insulin levels are elevated. Urine and blood sulfonylurea screen is negative. What is the next step?</span></span></p>",
      "unique_key": "Q8729471",
      "question_audio": null,
      "question_video": null,
      "map_id": 25637,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) CECT Abdomen</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation and laboratory results strongly suggest an insulinoma, a neuroendocrine tumor of the pancreas that secretes insulin, leading to hypoglycemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Weight gain and hypoglycemia:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Classic symptoms of insulinoma.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Low &beta;-OHB:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Indicates the body is not breaking down fats for energy due to excess insulin.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Elevated C-peptide and insulin:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Confirms endogenous insulin overproduction.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Negative sulfonylurea screen:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Rules out medication-induced hypoglycemia.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">The next step is to localize the tumor with imaging.</span></strong><span style=\"font-size:12.0pt\"> CECT Abdomen (contrast-enhanced computed tomography of the abdomen) is the most sensitive imaging modality for detecting insulinomas.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Selective arterial calcium stimulation:</span></strong><span style=\"font-size:12.0pt\">&nbsp;SACST (selective arterial calcium stimulation test) can be used if biochemical profile suggests endogenous hyperinsulinism but imaging is normal (to differentiate small insulinomas vs nesidioblastosis). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Measure serum IGF 2 levels:</span></strong><span style=\"font-size:12.0pt\">&nbsp;IGF-2 elevation would result in reflex suppression of endogenous insulin (hence insulin levels would be low).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Test for insulin autoantibodies:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This test is used for diagnosing autoimmune hypoglycemia,&nbsp;which is not supported by the clinical and laboratory findings in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CECT Abdomen is the most sensitive imaging modality for detecting insulinomas in patients presenting with weight gain, hypoglycemia, and elevated insulin/C-peptide levels.</span></span></span></p>",
      "correct_choice_id": 215645,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}